Antengene Corporation Limited (HK:6996) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antengene Corporation Limited has announced that the Malaysian National Pharmaceutical Regulatory Agency approved a New Drug Application for XPOVIO® for two new indications in the treatment of multiple myeloma. This milestone reflects the company’s commitment to expanding its oncology portfolio and the potential for XPOVIO® to offer novel treatment options for patients. The company advises shareholders and potential investors to exercise caution when dealing in its shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges